Here’s a helpful hint for you: Ignore market volatility. If you keep looking at your stocks, up-down swings can make you nervous. Invest with a long-term perspective, and the temporary functioning of the market will be much less boring.
The good news is that there are lots of stocks that offer excellent long-term returns. Here are three stocks that could double your money over the next few years.
Image Source: Getty Images.
1. CRISPR Therapeutic
CRISPR Therapeutic (Nasdaq: CRSP) Not too far from doubling this year, its share is close to 80%. But biotech stock should still have a lot of room.
You would especially like to see CRISPR Therapeutics lead pipeline candidate, CTX 1001. CRISPR and its major partners Vertix Pharmaceuticals Rare blood diseases are currently evaluating gene-acquisition therapy in early-stage clinical studies targeting beta-thalassemia and sickle cell disease. The companies have reported encouraging preliminary results of the study and expect to release additional data in the next few months. CTX1001 has the potential to essentially cure these diseases.
CRISPR therapeutic also has a great opportunity with its three allogeneic chimeric antigen receptor T-cell (CAR-T) therapy in early stage clinical trials. Allogeneic CAR-T treatment uses immune cells called T-cells from healthy individuals that are genetically engineered to target specific types of cancer, which then enter sick patients. Existing CAR-T treatments on the market use sick patients’ own T-cells – which should be much slower and more expensive than allogeneic therapies. CRISPR expects to report results by the end of this year in the early stages of its CAR-T therapy, CTXX1010.
Sure, there is a real risk that the CRISPR therapeutic gene-acquisition program will flop. But so far, investors have plenty of reasons to remain cautiously optimistic. If CTXX1001 or any of the company’s allogeneic CAR-T treatments are successful in clinical trials, CRISPR therapeutics should easily double in the very distant future.
2. Quickly
Fast (NYSE: FSLY) So far in 2020 investors have really taken on a wild ride. Tech stocks have seen seven swings of at least 20% in the last three months. But with the storm, Fastley is still up more than 350% to date.
The name of the company refers to the business underlying it. Focuses on accelerating the delivery of applications and data over the Internet through Content Delivery Network (CDN) and Edge Editing. Reduces the physical distance between servers and end users with a wide distribution platform of CDN servers. Edge computing takes a somewhat similar approach by moving application and data processing closer to the edge of the cloud – the point where corporate networks connect to the cloud.
The rapidly addressing market is currently over $ 35 billion. It can be much larger than that with the uninterrupted transfer of apps to the cloud. The company currently has less than 1% of this market at a rapid pace and offers the company great growth opportunities.
The company’s biggest customer is Ticket OK, a video sharing social network that has been at the center of a political fire recently. Until the deal is finally finalized to separate ticket ok from China-based owner Bitdense, Fastley’s shares could remain very volatile. However, the long-term prospects for the fast look pretty good.
3. Innovative Industrial Industrial Properties
If you have a U.S. If you have any doubts about how hot the cannabis market is, just look Innovative Industrial Industrial Properties (NYSE: IIPR). Shares of IIP have risen more than 60% so far this year and have come close to 600% in the last three years.
IIP Medical comes as a leading real estate investment trust (RIT) focused on the cannabis industry. It buys properties from medical cannabis operators, then converts them and returns the properties to .pater operators. This helps tenants increase cash while providing a steady income flow to the IIP.
The way to double up for an IIP is pretty simple: keep doing what it does. IIP currently has 63 medical cannabis properties in 1 state, which has 46 properties in 1 state at the end of 2019. The company’s lucrative dividend, which currently yields around 3%%, also makes it easier for investors to deliver tremendous returns.
It is possible that the U.S. Legalization of marijuana at the federal level could pave the way for more competitors to enter the IIP market. However, cannabis legalization is by no means a slam dunk. And even if IIP faces more competition in the future, growth in the U.S. cannabis market alone should enable this stock to continue its winning streak.
